Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: PVd Versus Vd in NDMM Patients With RI [Phase 2]
A Phase 2 trial comparing PVd versus Vd in newly diagnosed multiple myeloma patients with renal impairment is ongoing; status is currently U…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis [Phase 2]
Phase 2 trial of adoptive immunotherapy in relapsed hematological malignancies with early GVHD prophylaxis has completed enrollment and post…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 open-label multicenter trial evaluating isatuximab plus pomalidomide and dexamethasone with carfilzomib in relapsed or refractory mu…
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) [Phase 1, Phase 2]
Open-label, dose-escalation study of pemigatinib in advanced malignancies (FIGHT-101) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-03Clinical Trial Update: Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT [Phase 1, Phase 2]
Phase 1/2 trial evaluating escalating doses of thalidomide in combination with bortezomib and high-dose melphalan for autologous stem cell t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-28Clinical Trial Update: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) [Phase 2]
The National Cancer Institute provides an update on the phase 2 MATCH subprotocol evaluating taselisib (GDC-0032) in cancers with PIK3CA gen…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 trial evaluating cabozantinib to overcome carfilzomib resistance in refractory multiple myeloma has been terminated, with result…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
Clinical trial evaluating safety and activity of GSK2857916 plus pembrolizumab in relapsed/refractory multiple myeloma has completed Phase 1…
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM [Phase 1, Phase 2]
A phase 1/2 trial evaluating melphalan flufenamide (melflufen) plus dexamethasone with bortezomib or daratumumab in relapsed/refractory mult…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial update comparing bb2121 to standard regimens in relapsed and refractory multiple myeloma (RRMM).
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease [NA]
A completed clinical trial investigating combined bone marrow and renal transplantation for hematologic disorders in patients with end-stage…
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]
A Mayo Clinic-sponsored Phase 1/2 trial evaluated idasanutlin in combination with ixazomib citrate and dexamethasone in relapsed multiple my…
-
CLINICAL_TRIALS trial_result · 2022-11-29Clinical Trial Update: Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) [Phase 2]
A Phase 2 MATCH subprotocol study evaluates afatinib for cancers with HER2 genetic changes; results were posted in 2022 and the trial status…
-
CLINICAL_TRIALS trial_result · 2022-11-23Clinical Trial Update: Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 trial update on pralatrexate plus romidepsin in relapsed/refractory lymphoid malignancies and multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 study assessing safety, pharmacokinetics, and efficacy of oral CC-223 in advanced solid tumors, non-Hodgkin lymphoma, or multiple …
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Phase 2]
A Phase 2 trial evaluating pembrolizumab in combination with ixazomib citrate and dexamethasone for relapsed multiple myeloma has completed …
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-10-17Clinical Trial Update: Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial of elotuzumab combined with lenalidomide and dexamethasone in transplant-eligible newly diagnosed multiple myeloma pa…
-
CLINICAL_TRIALS trial_result · 2022-10-03Clinical Trial Update: Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma [Phase 2]
Phase 2 trial evaluating combination chemotherapy and thalidomide in stage I–III multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) [Phase 2]
Phase 2 MATCH subprotocol G trial evaluating crizotinib for cancers with ROS1 genetic changes reports updated results and current status (Ph…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide [Phase 3]
Phase 3 trial evaluating extended VRD, Isa-VRD, and Isa-V-Iberdomide for newly diagnosed multiple myeloma patients candidates for autologous…
-
CLINICAL_TRIALS trial_result · 2022-09-23Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant in newly diagnosed multiple myel…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) [Phase 2]
Phase 2 MATCH subprotocol F study evaluating crizotinib for cancers with ALK genetic changes. The trial is currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance [Phase 2]
Phase 2 clinical trial evaluating busulfan/melphalan conditioning for autologous stem cell transplant with lenalidomide maintenance in multi…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis [Phase 1, Phase 2]
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in previously untreated symptomatic multiple myeloma or AL amyloidosis. …